Business Description
TG Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US88322Q1085
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.89 | |||||
Equity-to-Asset | 4.09 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 2.05 | |||||
Interest Coverage | 4.01 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.55 | |||||
Beneish M-Score | 71.93 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1063 | |||||
3-Year FCF Growth Rate | 51.5 | |||||
3-Year Book Growth Rate | -34 | |||||
Future 3-5Y Total Revenue Growth Rate | 43.16 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.75 | |||||
9-Day RSI | 19.8 | |||||
14-Day RSI | 18.32 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Days Inventory | 637.9 | |||||
Days Sales Outstanding | 36.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.5 | |||||
Shareholder Yield % | -0.14 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.53 | |||||
Operating Margin % | 16.71 | |||||
Net Margin % | 14.24 | |||||
FCF Margin % | -10.86 | |||||
ROE % | 10.74 | |||||
ROA % | 14.18 | |||||
ROIC % | 57.24 | |||||
ROC (Joel Greenblatt) % | 133.35 | |||||
ROCE % | 22.27 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 75.02 | |||||
Forward PE Ratio | 68.91 | |||||
PE Ratio without NRI | 75.02 | |||||
PS Ratio | 8.71 | |||||
PB Ratio | 1.67 | |||||
Price-to-Tangible-Book | 1.67 | |||||
EV-to-EBIT | 45.53 | |||||
EV-to-EBITDA | 45.28 | |||||
EV-to-Revenue | 8.45 | |||||
EV-to-Forward-Revenue | 8.09 | |||||
EV-to-FCF | -77.8 | |||||
Price-to-Graham-Number | 2.36 | |||||
Earnings Yield (Greenblatt) % | 2.2 | |||||
FCF Yield % | -1.23 |